Hwang Catherine J, Nichols Erin E, Chon Brian H, Perry Julian D
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, OH, USA.
Eur J Ophthalmol. 2022 May;32(3):NP46-NP49. doi: 10.1177/1120672121991042. Epub 2021 Feb 1.
Thyroid eye disease is an auto-immune mediated orbitopathy which can cause dysthyroid compressive optic neuropathy. Traditional management of active thyroid eye disease includes temporizing high-dose steroids, orbital radiation and surgical decompression, which each possess significant limitations and/or side effects. Teprotumumab is an IGF-IR inhibitor recently FDA-approved for active thyroid eye disease. The authors report reversal of bilateral dysthyroid compressive optic neuropathy managed medically utilizing teprotumumab.
甲状腺眼病是一种自身免疫介导的眼眶病，可导致甲状腺功能异常性压迫性视神经病变。活动性甲状腺眼病的传统治疗方法包括使用大剂量类固醇进行临时治疗、眼眶放疗和手术减压，这些方法都有显著的局限性和/或副作用。替普罗单抗是一种胰岛素样生长因子1受体（IGF-IR）抑制剂，最近被美国食品药品监督管理局（FDA）批准用于治疗活动性甲状腺眼病。作者报告了使用替普罗单抗药物治疗双侧甲状腺功能异常性压迫性视神经病变的逆转情况。
